Psagot Investment House Ltd. cut its holdings in Pfizer Inc. (NYSE:PFE) by 7.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 180,884 shares of the biopharmaceutical company’s stock after selling 14,422 shares during the quarter. Psagot Investment House Ltd.’s holdings in Pfizer were worth $6,458,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of the stock. Shine Investment Advisory Services Inc. purchased a new stake in Pfizer during the second quarter worth $102,000. Mckinley Capital Management LLC Delaware purchased a new stake in Pfizer during the second quarter worth $103,000. Herndon Capital Management LLC purchased a new stake in Pfizer during the second quarter worth $120,000. Lipe & Dalton boosted its position in Pfizer by 6.9% during the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock worth $155,000 after purchasing an additional 300 shares in the last quarter. Finally, Legacy Advisors LLC purchased a new stake in Pfizer during the third quarter worth $164,000. Hedge funds and other institutional investors own 70.12% of the company’s stock.
A number of research firms have commented on PFE. BMO Capital Markets set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Thursday, February 15th. Berenberg Bank set a $36.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Tuesday, January 30th. Leerink Swann boosted their price target on Pfizer from $35.00 to $38.00 and gave the stock a “market perform” rating in a report on Wednesday, January 31st. UBS Group set a $42.00 price target on Pfizer and gave the stock a “buy” rating in a report on Wednesday, January 31st. Finally, Societe Generale set a $40.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Wednesday, January 31st. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $39.45.
Pfizer Inc. (NYSE:PFE) opened at $35.74 on Friday. The company has a market capitalization of $213,040.00, a price-to-earnings ratio of 10.15, a P/E/G ratio of 2.03 and a beta of 0.94. Pfizer Inc. has a 12 month low of $31.67 and a 12 month high of $39.43. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.06. The firm had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The business’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.47 earnings per share. equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be paid a $0.34 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a yield of 3.81%. The ex-dividend date is Thursday, February 1st. Pfizer’s dividend payout ratio is presently 38.64%.
Pfizer announced that its Board of Directors has approved a stock buyback program on Monday, December 18th that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.
In related news, insider Alexander R. Mackenzie sold 6,750 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the transaction, the insider now directly owns 103,458 shares in the company, valued at $3,827,946. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Rady A. Johnson sold 8,000 shares of the company’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the transaction, the executive vice president now owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/23/psagot-investment-house-ltd-has-6-46-million-position-in-pfizer-inc-pfe.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.